Kiniksa Pharmaceuticals International, PLC 8-K filings

Kiniksa Pharmaceuticals announced robust second quarter 2026 financial results, driven by significant growth in ARCALYST net product revenue and positive clinical trial updates for KPL-387.

Kiniksa Pharmaceuticals confirms the re-election of three directors and the ratification of PwC as auditors following its 2026 Annual Meeting.

Kiniksa Pharmaceuticals International, plc has entered into a deed of waiver with Baker Bros. Advisors LP, impacting conversion rights of certain shareholders.

Kiniksa Pharmaceuticals Chief Strategy Officer Eben Tessari will resign effective May 15, 2026, to transition into a consulting and advisory role.

Kiniksa Pharmaceuticals announced robust first quarter 2026 financial results, driven by significant growth in ARCALYST net product revenue and an increased full-year revenue guidance.

Kiniksa Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by significant ARCALYST sales growth and a positive outlook for 2026.

Kiniksa Pharmaceuticals International, plc announced the appointments of Ross Moat as Chief Operating Officer and Eben Tessari as Chief Strategy Officer, effective January 10, 2026.

Kiniksa Pharmaceuticals announced unaudited 2025 full-year ARCALYST net product revenue of $677.5 million, representing 62% year-over-year growth, and projected 2026 revenue of $900-$920 million.

Kiniksa Pharmaceuticals reported strong third-quarter 2025 financial results, driven by 61% year-over-year ARCALYST revenue growth and an increased full-year sales guidance.

Kiniksa Pharmaceuticals raises its 2025 ARCALYST revenue guidance and provides updates on its clinical pipeline, including KPL-387 and KPL-1161.

Kiniksa Pharmaceuticals announced robust second quarter 2025 financial results, driven by significant ARCALYST revenue growth and an upward revision of its full-year 2025 net product revenue guidance.

Kiniksa Pharmaceuticals International, plc announced an increase in its 2025 ARCALYST net product sales guidance and confirmed its KPL-387 Phase 2/3 clinical trial for recurrent pericarditis is on track to initiate in mid-2025.

Kiniksa Pharmaceuticals International, plc announced that all proposals, including the re-election of directors, appointment of auditors, and authorization for share allotment, were duly passed at its Annual Meeting of Shareholders held on June 3, 2025.

Kiniksa Pharmaceuticals announced positive first quarter 2025 financial results, driven by strong ARCALYST sales, and increased its full-year revenue guidance for ARCALYST.

Kiniksa Pharmaceuticals introduces a long-term incentive plan for executive officers, linking compensation to the achievement of key milestones in the development and approval of KPL-387 for recurrent pericarditis.

Kiniksa Pharmaceuticals reports positive ARCALYST sales growth, discontinues abiprubart development, and advances KPL-387 and KPL-1161 programs.

Kiniksa Pharmaceuticals announced a 79% year-over-year growth in ARCALYST net product revenue for 2024, reaching $416.4 million, and projects continued growth in 2025.

Kiniksa Pharmaceuticals announced a 73% year-over-year increase in ARCALYST net product revenue for Q3 2024, raising its full-year revenue guidance for the drug.

Kiniksa Pharmaceuticals has increased its board size and appointed M. Cantey Boyd as a new director, effective October 4, 2024.

Kiniksa Pharmaceuticals announced positive second quarter 2024 financial results, highlighted by a 90% year-over-year increase in ARCALYST net product revenue and an upward revision of its 2024 revenue guidance.

Kiniksa Pharmaceuticals International, plc has successfully completed its redomiciliation from Bermuda to the United Kingdom, becoming the successor issuer.

Kiniksa Pharmaceuticals has entered into a long-term manufacturing agreement with Samsung Biologics for its ARCALYST drug substance.

Kiniksa Pharmaceuticals has obtained court approval for its planned redomiciliation from Bermuda to the United Kingdom, with the move expected to be completed around June 27, 2024.

Kiniksa Pharmaceuticals successfully held its Annual Meeting and a special court-ordered meeting, approving the election of directors, the appointment of auditors, executive compensation, and a scheme of arrangement for redomiciliation.

Kiniksa Pharmaceuticals announced strong first quarter 2024 financial results, highlighted by an 85% year-over-year increase in ARCALYST net product revenue and an upward revision of its 2024 revenue guidance.

Kiniksa Pharmaceuticals plans to initiate a Phase 2b trial of abiprubart in Sjogrens Disease and has released positive topline data from a Phase 2 rheumatoid arthritis trial, while also expecting to remain cash flow positive.

Kiniksa Pharmaceuticals plans to move its principal holding company's place of incorporation from Bermuda to the United Kingdom, pending shareholder and court approvals.

Kiniksa Pharmaceuticals announced positive financial results for 2023, driven by strong ARCALYST sales, and provided updates on its clinical pipeline, including plans for a new abiprubart trial.